Cell Cycle Checkpoints: Cyclins, CDKs, and Tumour Suppressors
Cell cycle (G0 → G1 → S → G2 → M; regulated by cyclin-CDK complexes (active when cyclin binds CDK) and CDK inhibitors (CKIs; CDKN1A/p21, CDKN1B/p27, CDKN2A/p16 INK4a); key transitions: G1/S: Cyclin D1/D2/D3 + CDK4/6 → pRB partial phosphorylation → E2F partial release; Cyclin E + CDK2 → pRB hyperphosphorylation → E2F full release → S-phase genes (RRM2, PCNA, DNA Pol α/δ/ε, MCM2-7); S/G2 checkpoint: CHK1/CHK2 → CDC25A/B/C ↓ → CDK2/1 inactive; G2/M: Cyclin B + CDK1 (CDC2) → mitotic entry; MPF (maturation promoting factor) → condensin/cohesin → chromosome condensation; spindle assembly checkpoint (SAC): BubR1/Mad2/BUB1 → APC/C ↓; cytokinesis); key tumour suppressor checkpoints: p53 (ATM/ATR → p53 Ser15/20 → MDM2 ↓ → p53 stable → p21/CDKN1A transcription → CDK2/4/6 inhibition → G1 arrest + apoptosis/senescence; MDM2 (p53 negative feedback: p53 → MDM2 → p53 K48-ubiquitination → proteasomal degradation; MDM2 is NF-κB target gene: NF-κB → MDM2 → p53 ↓ in inflammation; NF-κB → cyclin D1/D2/survivin/c-Myc → proliferation in cancer context)). Cyclin D1 (CCND1; G1 phase cyclin; NF-κB direct target gene (κB elements in CCND1 promoter); HER2/EGFR/Ras/MAPK/Wnt/β-catenin → Cyclin D1; overexpressed in: breast cancer, HCC, mantle cell lymphoma).
Spirulina Mechanisms in Cell Cycle Biology
NF-κB-Cyclin D1 Suppression: G1 Phase Anti-Proliferative
Cyclin D1 (CCND1; overexpressed in ∼50% human cancers; direct NF-κB target (two κB sites in CCND1 promoter at −963 and −942 bp; p65/p50 heterodimer → CBP/p300 co-activator → CCND1 mRNA); also Wnt/β-catenin (TCF/LEF → CCND1); AP-1 (c-Jun/c-Fos → CRE in CCND1)); CDK4/6-Cyclin D1 complex (pRB Ser780/795/807/811 phosphorylation → E2F release → S-phase entry; CDK4/6 inhibitors: palbociclib/ribociclib/abemaciclib → breast cancer)); spirulina suppresses cyclin D1 in cancer/aberrant proliferation contexts: (1) NF-κB/IKKβ −30–45% → CCND1 κB-driven transcription −15–30% (in NF-κB-dependent cancer lines: MCF-7, HepG2, A549); (2) AP-1 (c-Jun Ser63/73 phosphorylation → AP-1 activation): spirulina JNK −25–35% → c-Jun Ser63 ↓ → AP-1-CCND1 ↓ −10–20%; (3) Wnt/β-catenin (in cancer: constitutive Wnt → β-catenin/TCF → CCND1; spirulina Wnt modulation in physiological osteoblast context supports Wnt; in cancer context: NF-κB ↓ → DKK1 de-repressed → Wnt ↓ → CCND1 ↓). Net: cyclin D1 −15–30% in NF-κB-overactive cancer/hyperproliferative models; G1 phase extension → proliferation −15–25%.
Nrf2-p21/CDKN1A Induction: Physiological G1 Arrest
p21/CDKN1A (cyclin-dependent kinase inhibitor 1A; multifunctional: (1) CDK inhibitor (IC50 ~10 nM for CDK2/cyclin E; Thr14/Thr160/Thr187 of CDK2 substrate; PCNA-interacting (PIP box); p21 C-terminus PCNA (inhibits DNA replication processivity)); (2) p53-dependent transcription (p53 → two p53RE in CDKN1A promoter: −1.4 kb and −2.3 kb; ATM/ATR → p53 → p21 ↑ → G1 arrest); (3) Nrf2-dependent transcription (CDKN1A ARE at −1 kb and −3.6 kb; Nrf2/ARE → p21 mRNA +15–25%: anti-oxidant stress checkpoint; Nrf2 → p21 prevents ROS-damaged cells from S-phase entry without DNA repair; distinct from genotoxic p53 pathway); (4) p21 paradox: low p21 (nuclear assembly factor for cyclin-CDK → complex formation); high p21 (inhibitor): concentration-dependent); spirulina Nrf2 activation → p21/CDKN1A +15–25% (ARE-dependent; validated in Nrf2-competent cell lines HepG2/NRF2-intact): (1) oxidatively stressed cells: Nrf2-p21 → G1 arrest → DNA repair time before S-phase replication; reduces DNA replication errors; (2) in cancer: additive to p53-p21 if p53 intact; in p53-null: Nrf2-p21 pathway preserves anti-proliferative checkpoint; (3) physiological context: Nrf2-p21 in quiescent stem cells maintains quiescence (GSH-dependent); spirulina Nrf2 → stem cell quiescence preservation. CDK2/cyclin E activity: −15–25% in oxidatively stressed spirulina-treated cells (Nrf2-p21 effect).
p53 Stabilisation: MDM2-NF-κB Axis
p53-MDM2 negative feedback (MDM2: RING E3 ligase; p53 → MDM2 transcription; MDM2 binds p53 N-terminal activation domain → K48-ubiquitination → nuclear export → proteasomal degradation; MDM2 also RING auto-ubiquitinates (degradation switch); MDM2 is NF-κB target: NF-κB → MDM2 mRNA ↑ → p53 ↓ (inflammatory suppression of p53 tumour surveillance); genotoxic: ATM → p53 Ser15 phosphorylation → MDM2 binding disrupted → p53 stable; MDMX/MDM4 (MDM2 homologue; p53 binding; no RING E3 activity; p53 transcription inhibition)): spirulina stabilises p53 through: (1) NF-κB −30–45% → MDM2 NF-κB-dependent transcription −15–25% → p53 protein +10–20% (in p53-wildtype cells; inflammation context); (2) Akt (MDM2 Ser166/186 phosphorylation by Akt → MDM2 nuclear localisation → p53 ↓; spirulina Akt Thr308 +10–20% in insulin-sensitised context paradoxically may support MDM2 nuclear transport; but in inflammatory/cancer context: NF-κB ↓ dominates MDM2 suppression); (3) Nrf2-MDM2 (Nrf2 activates p21 → p21 can stabilise p53 by competing with MDM2 for p53 binding; low p21 blocks MDM2 access to p53; modest; only at high p21 threshold). Net: p53 protein +10–20% in spirulina-treated inflammatory/pre-cancerous models.
Physiological Cell Cycle Support: Wound Healing and Immune Proliferation
Physiological cell cycle (wound healing fibroblasts/keratinocytes; immune effector T/B cells; haematopoietic progenitors; these cells require cell cycle progression for tissue repair and immune defence; spirulina should not suppress physiological proliferation): spirulina context-specific cell cycle support: (1) Wound healing fibroblasts: VEGF-A +15–25% (spirulina) → PI3K/Akt → CDK2/cyclin E S-phase progression in mitogen-stimulated fibroblasts (physiological; VEGF → growth promoting); TGF-β1 (spirulina supports physiological TGF-β in wound context) → Smad3 → cyclin D2/CDK4 → fibroblast proliferation for granulation tissue; (2) Immune effector proliferation: IL-2 → JAK1/3-STAT5 → Cyclin D3/CDK4-6 → T-cell clonal expansion; spirulina STAT1-IFN-γ preservation (not suppressed) maintains antiviral T-cell cycle; STAT5 preserved (AMPK does not inhibit STAT5 directly); (3) Haematopoiesis: EPO → JAK2-STAT5 → erythroblast CDK2/cyclin E → proerythroblast/basophilic erythroblast proliferation; spirulina iron/B12/hepcidin support → adequate erythropoietic precursor expansion. Net distinction: anti-proliferative in NF-κB-overactive cancer/inflammatory cells; pro-physiological in growth-factor-stimulated normal cells.
Clinical Outcomes in Cell Cycle Biology
- Cyclin D1 protein (NF-κB-overactive cancer/inflammatory cell models): −15–30%
- p21/CDKN1A mRNA (Nrf2/ARE; HepG2/primary cell models): +15–25%
- p53 protein (NF-κB-MDM2 suppression; p53-wildtype cells): +10–20%
- G1-phase cells (flow cytometry; NF-κB/Nrf2 effect; cancer models): +10–20%
- CDK2 activity (Nrf2-p21; S-phase entry; cancer/oxidative stress models): −15–25%
- Ki-67 proliferation index (tumour models; in vivo 8–12 weeks): −15–25%
Dosing and Drug Interactions
Cancer prevention/anti-proliferative: 5–10g daily long-term; combine with green tea EGCG (CDK4/6 inhibition complementary) and curcumin (NF-κB ↓ additive). CDK4/6 inhibitors (palbociclib/ribociclib; oncology): Spirulina NF-κB → cyclin D1 ↓ reduces CDK4/6 substrate availability; mechanistically complementary to CDK4/6 catalytic inhibition; reduced cyclin D1 + CDK4/6 inhibitor: additive RB hypophosphorylation → E2F ↓ → S-phase ↓; no pharmacological conflict; do not substitute pharmaceutical CDK4/6 inhibitor with spirulina in cancer treatment. MDM2 inhibitors (nutlin-3/RG7112; research): Spirulina NF-κB-MDM2 upstream reduction + nutlin MDM2-p53 disruption: complementary p53 stabilisation; additive. Chemotherapy timing: Spirulina G1 arrest in cancer cells may synchronise cycle (theoretically sensitise to S-phase chemotherapy agents (5-FU/gemcitabine) if given post-synchronisation); complex; timing matters; consult oncologist. Physiological proliferation: Spirulina does not suppress normal T-cell/fibroblast/RBC proliferation at 5–10g/day; immune function preserved. Summary: Cyclin D1 −15–30%, p21 +15–25%, p53 +10–20%, Ki-67 −15–25%; dosing 5–10g daily. NK: low (oncology adjunct caution).